HUTCHMED (NASDAQ:HCM) Share Price Crosses Below 50-Day Moving Average – Time to Sell?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $13.71 and traded as low as $11.38. HUTCHMED shares last traded at $11.52, with a volume of 139,099 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Morgan Stanley set a $13.60 target price on HUTCHMED in a research note on Thursday, May 28th. Weiss Ratings cut HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 1st. Bank of America cut their target price on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. Finally, Wall Street Zen downgraded HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, HUTCHMED has a consensus rating of “Hold” and a consensus price target of $16.80.

HUTCHMED Stock Performance

The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average price of $13.71 and a 200-day moving average price of $14.16.

HUTCHMED (NASDAQ:HCM) last announced its quarterly earnings results on Friday, March 6th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.50 by ($2.49). The firm had revenue of $135.42 million during the quarter, compared to analysts’ expectations of $290.50 million. On average, research analysts predict that HUTCHMED will post 0.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Amundi lifted its holdings in HUTCHMED by 4.0% in the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after acquiring an additional 8,916 shares during the period. Janney Montgomery Scott LLC bought a new position in HUTCHMED in the first quarter valued at about $365,000. State Street Corp lifted its holdings in HUTCHMED by 1.2% in the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after acquiring an additional 3,801 shares during the period. Renaissance Technologies LLC lifted its holdings in HUTCHMED by 3.0% in the fourth quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $1,798,000 after acquiring an additional 3,900 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in HUTCHMED by 157.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock valued at $746,000 after acquiring an additional 34,248 shares during the period. 8.82% of the stock is owned by institutional investors.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.